PJP vs. IYH: Which Healthcare ETF Is the Better Buy?

This is less a healthcare call than a packaging call: the real economic exposure in both vehicles is still dominated by the same large-cap pharma complex, so the apparent diversification benefit is thinner than it looks. That means incremental flows into the broader fund are likely to support the same three mega-cap names rather than the rest of the healthcare stack, which can amplify crowding in LLY/ABBV/JNJ while leaving device, services, and smaller innovators relatively ignored. In other words, if healthcare is being owned as a defensive sleeve, the market is increasingly paying for the same single-name factor twice: once in sector allocation and again inside the ETF holdings.

The near-term risk is that the recent relative strength in pharma is already consensus within healthcare allocators, so the concentrated basket is more exposed to any disappointment in pricing, pipeline, or litigation headlines over the next 1-3 months. A pullback in just one of the three anchor names would matter more for PJP than the broader fund because concentration cuts both ways; conversely, if LLY continues to re-rate on growth durability, both wrappers will move together and the fee/yield difference will matter less than the embedded single-name beta. The structural, 6-18 month issue is that lower-cost broad healthcare products should keep winning net asset flows if investors remain defensive, which is a quiet tailwind for IYH even if it lags on pure momentum.

The contrarian read is that the market may be overestimating how much diversification it is getting from a 100-stock healthcare ETF when one-third of assets sit in three names. That argues for treating the choice as a view on the same pharma giants rather than on healthcare beta broadly. If the next catalyst is a negative read-through on drug pricing or a de-rating in LLY, the more concentrated fund should underperform mechanically; if the catalyst is sustained pharma leadership, PJP can keep outrunning the broader fund despite the higher fee. The key falsifier is simple: if relative performance of the large-cap pharma trio rolls over versus managed care/devices over the next quarter, the momentum case for the concentrated ETF breaks quickly.